Market Research Logo

Boehringer Ingelheim GmbH - Product Pipeline Review - 2016

Boehringer Ingelheim GmbH - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Boehringer Ingelheim GmbH
  • The report provides overview of Boehringer Ingelheim GmbH including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Boehringer Ingelheim GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Boehringer Ingelheim GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Boehringer Ingelheim GmbH
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Boehringer Ingelheim GmbH’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Boehringer Ingelheim GmbH Snapshot
Boehringer Ingelheim GmbH Overview
Key Information
Key Facts
Boehringer Ingelheim GmbH - Research and Development Overview
Key Therapeutic Areas
Boehringer Ingelheim GmbH - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Boehringer Ingelheim GmbH - Pipeline Products Glance
Boehringer Ingelheim GmbH - Late Stage Pipeline Products
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products
Boehringer Ingelheim GmbH - Early Stage Pipeline Products
Boehringer Ingelheim GmbH - Drug Profiles
(empagliflozin + linagliptin)
(linagliptin + metformin hydrochloride ER)
(olodaterol hydrochloride + tiotropium bromide)
idarucizumab
(empagliflozin + metformin hydrochloride XR)
adalimumab biosimilar
afatinib dimaleate
bevacizumab biosimilar
empagliflozin
nintedanib
risankizumab
rituximab biosimilar
volasertib trihydrochloride
BI-1026706
BI-1361849
BI-144807
BI-409306
FX-125L
HM-61713
BI-836826
BI-836845
BI-836858
BI-1005273
BI-1060469
BI-113608
BI-416970
BI-425809
BI-443651
BI-655064
BI-655088
BI-655130
BI-685509
BI-836880
BI-836909
BI-853520
BI-860585
BI-894999
PXS-4728A
Small Molecule for Oncology
AR-116082
BI-113823
BI-1467335
BI-186908
BI-207524 Follow-Up
BI-703704
BI-882370
CNX-012
CNX-012570
linagliptin
Monoclonal Antibody for Ophthalmology
olcegepant
Small Molecule 2 for Oncology
Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
Small Molecule 3 for Oncology
Small Molecule for Respiratory Diseases
Small Molecule to Agonize Glucocorticoid Receptor for Inflammation
Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection
Small Molecules for Respiratory Disorders
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy
Synthetic Peptide for CardioMetabolic Disease
Antibody for Oncology
BI-665915
Small Molecule for HIV
Small Molecule for HIV-1 Infection
Small Molecule to Agonize Glucocorticoid Receptor
Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders
Small Molecules for Oncology
Small Molecules for Schizophrenia
Small Molecules for Undisclosed Indication
Small Molecules to Inhibit K-Ras for Oncology
Small Molecules to Inhibit Kinases for Oncology
Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Disorders
Boehringer Ingelheim GmbH - Pipeline Analysis
Boehringer Ingelheim GmbH - Pipeline Products by Target
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action
Boehringer Ingelheim GmbH - Recent Pipeline Updates
Boehringer Ingelheim GmbH - Dormant Projects
Boehringer Ingelheim GmbH - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Boehringer Ingelheim GmbH, Key Information
Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH - Pipeline by Indication, 2016
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2016
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016
Boehringer Ingelheim GmbH - Pre-Registration, 2016
Boehringer Ingelheim GmbH - Phase III, 2016
Boehringer Ingelheim GmbH - Phase II, 2016
Boehringer Ingelheim GmbH - Phase I, 2016
Boehringer Ingelheim GmbH - Preclinical, 2016
Boehringer Ingelheim GmbH - Discovery, 2016
Boehringer Ingelheim GmbH - Pipeline by Target, 2016
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2016
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2016
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2016
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2016
Boehringer Ingelheim GmbH, Subsidiaries
List of Figures
Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2016
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016
Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2016
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016
Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report